SEC Form D private-offering filing

Solstice Oncology, Inc.

Name: Solstice Oncology, Inc. - new SEC Form D private-offering filing, Boston, MA
Published: 2026-03-09

A new SEC Form D private-offering notice from Boston, MA, a $298,400,851 filer-stated offering target in Biotech. The source filing is one click away.

Solstice Oncology, Inc. Verified via SEC Form D

Clinical-stage Boston biotech developing HBM4003, an anti-CTLA-4 heavy-chain-only antibody licensed from Harbour BioMed, for melanoma, colorectal cancer and other solid tumors.

Filed 2026-03-09Filed to raise $298,400,851First money in 2026-02-20Raised so far $121,260,306HQ (as filed) Boston, MASector Biotech ✓Stage (inferred) LateCall status Call-ready

Source linked the Form D on EDGAR↗Named in the filing 7 executives & directors

Open this row on the live feed →More new filings in Massachusetts →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.